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Abstract
Background: The anti-malarial activity of maslinic acid (MA), a natural triterpene which has been previously shown
to exert a parasitostatic action on Plasmodium falciparum cultures, was analysed in vivo by using the Plasmodium
yoelii 17XL murine model.
Methods: ICR mice were infected with P. yoelii and treated with a single dose of MA by a intraperitoneal injection
of MA (40 mg kg
-1 day
-1) followed by identical dose administration for the following three days. Parasitaemia and
accumulation of intraerythrocytic stages was monitored microscopically. To assess protective immunity, cured mice
were challenged with the same dose of parasites 40 days after recovery from the primary infection and
parasitaemia was further monitored for 30 days. Humoral response was tested by ELISA and visualization of specific
anti-P. yoelii antibodies was performed by Western-blotting.
Results: ICR mice treated with MA increased the survival rate from 20% to 80%, showing an arrest of parasite
maturation from day 3 to 7 after infection and leading to synchronization of the intraerythrocytic cycle and
accumulation of schizonts by day 6, proving that MA also behaves as a parasitostatic agent in vivo. Mice which
survived the primary infection displayed lower rates of parasitic growth, showing a decline of parasitaemia after
day 15, and complete clearance at day 20. These mice remained immunoprotected, showing not malaria
symptoms or detectable parasitaemia after rechallenge with the same lethal strain. The analysis of specific
antibodies against P. yoelii, present in mice which survived the infection, showed a significant increase in the
number and intensity of immunoreactive proteins, suggesting that the protected mice may trigger a strong
humoral response.
Conclusion: The survival increase observed in MA-treated mice can be explained considering that the
parasitostatic effect exerted by this compound during the first days of infection increases the chances to develop
effective innate and/or acquired immune responses. MA may represent a new class of anti-malarial compounds
which, as a consequence of its parasitostatic action, favours the development of more effective sterilizing immune
responses.
Background
Despite the extensive research carried out to find new
anti-malarial drugs or antigenic targets which can be
eventually used in vaccine formulations, most of these
efforts have been unsuccessful so far due to several fac-
tors, such as the emergence of resistant strains, the
requirement of both low-toxicity and low-cost anti-
malarials, and the failure to develop a practical vaccine
that prevents malaria.
There is increasing evidence that the in vivo response
to anti-malarial treatments is affected by factors other
than the intrinsic susceptibility of Plasmodium species
to the drugs. The parasite load, innate host resistance to
the parasite [1] and naturally acquired immunity are
known to play an important role in the infection pro-
gress and the outcome of the treatment with anti-malar-
ials (reviewed by [2,3]). While most evidence on this
subject was gathered from epidemiological surveys in
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performed using animal models to reproduce the influ-
ence of anti-malarial drug-treatments on the onset of
acquired immunity. In a recent report, immunization of
BALB/c mice with live Plasmodium yoelii nonlethal
strains under curative chloroquine doses showed to con-
fer protection against both blood stage and sporozoite
parasites [4]. Similarly, a combination of low doses of
interleukin 12 and chloroquine induced mice immunity
against reinfection with Plasmodium chabaudi [5]. The
use of chloroquine in immunization procedures in
humans has also been tested in a proof-of-concept clini-
cal study [6], which showed that chloroquine-treated
volunteers achieve higher levels of protection after
inoculation with very small doses of intact sporozoites
as compared to vaccination procedures based in the
inoculation of radiation-attenuated sporozoites [7]. A
plausible explanation of such behaviour is that the expo-
sure to the pre-erythrocytic stages of infection, which is
not avoided by chloroquine treatment, may enhance the
immune response by favouring the presentation of anti-
gens [8]. Anti-malarial drugs showing intra-erythrocytic
parasitostatic effect might produce the immunization of
the host by a similar mechanism, in which a controlled
parasitaemia level would enhance antigen presentation
to the immune system.
Maslinic acid (MA), a natural pentacyclic triterpenoid
found in the olive fruits, has been recently shown to dis-
play a parasitostatic effect on the intraerythrocytic cycle
of in vitro cultured Plasmodium falciparum [9]. The
anti-malarial activity was dose-dependent, showing para-
sitocidal effect at 100 μM, while a non-permanent arrest
of parasite maturation in infected erythrocytes was
observed at 30 μM .T h ep a r a s i t ed e v e l o p m e n tf r o m
early ring to late trophozoite was halted as long as MA
was present in the culture, and growth was resumed
upon removal of the triterpene. As a natural product
present in the human diet, MA can be regarded as safe
in therapeutic applications. In addition, it has been
shown that MA displays low toxicity on non-tumoral
cells [10,11]. MA can be readily obtained in large quan-
tities from olive pomace oil, a byproduct of olive proces-
sing, fulfilling thus important requirements for its
eventual clinical application.
While parasitostatic drugs may not completely avoid
the infective process like other currently used com-
pounds, they might eventually mimic the effect of vacci-
nation with inactivated parasite, as the presence of
growth-arrested infected erythrocytes would trigger an
enhanced immune response by the host.
In the present study, the protection exerted by MA
against the P. yoelii 17XL lethal strain in a model mice
system was investigated. The possible effect of MA on
the development of protective acquired immunity to
malaria was also tested, and its use as a model for the




The rodent malaria parasite P. yoelii 17XL (MRA-267)
was obtained from the Malaria Research and Reference
Resource Center, maintained by serial blood passage in
m i c ea n dt h ei n f e c t e db l o o dw a ss t o r e da t- 8 0 ° C .R a n -
dom-bred ICR female mice (Hsd:ICR[CD-1
®]) 6-8
weeks old, were purchased from Harlan Laboratories.
T h em i c ew e r eh o u s e du n d e rs t a n d a r dc o n d i t i o n so f
light and temperature in the Animal Housing Facility at
Complutense University. All mice were fed ad libitum
on a commercial diet. In vivo experiments were carried
out in accordance with national and international guide-
lines for animal care, using protocols approved by the
Animal Experimentation Committee of the Complutense
University.
Assay for in vivo anti-malarial activity
Maslinic acid (MA) was kindly provided by Dr. Andrés
García-Granados from the University of Granada
(Spain). The stock solution (200 mM) was prepared in
100% dimethyl sulfoxide (DMSO).
The in vivo anti-malarial activity of MA was analysed
by using a four-day-blood suppressive test as previously
described [12]. Briefly, mice were inoculated by intraper-
itoneal injection (i.p) of 10
7 red blood cells from P. yoe-
lii -infected mice. The chemotherapy treatment started
2 h later (day 1) with a single dose of MA by a intraper-
itoneal injection of MA (40 mg kg
-1 day
-1)f o l l o w e db y
identical dose administration for the following 3 days.
The control groups received DMSO 5% in phosphate
buffered saline solution. The parasitaemia was moni-
tored daily by microscopic examination of Wright’s-
stained thin blood smears.
To assess protective immunity, cured mice were chal-
lenged with the same dose of parasites 40 days after
recovery from the primary infection and parasitaemia
was further monitored for 30 days.
IgG and IgM concentration in mice serum
Plasmodium yoelii specific antibodies present in sera
from challenged mice were quantified by mouse-IgG
and mouse-IgM ELISA kits (Bethyl Laboratories, Inc).
96-well plates were coated with 100 μL/well of each
standard or sample, covered and incubated at room
temperature (20-25°C) for 1 hour. After several washes,
the wells were incubated for 1 hour with 100 μLo ft h e
primary anti-IgG or anti-IgM antibodies followed by 100
μL of enzyme-labelled secondary antibody for 30 min-
utes. The enzymatic reaction was developed following
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reaction product was recorded in a microplate reader at
450 nm and immunoglobulin concentrations were calcu-
lated from standard curves.
Western blot analysis
The specificity of immunoglobulins against P. yoelii pro-
teins was further ascertained by immunoblotting. The
parasite antigens were obtained from P. yoelii infected
erythrocytes (iRBC) collected from mice showing 50%
parasitaemia. The lysates were prepared with saponin in
PBS (final concentration 0.1% w/v) by disrupting the
erythrocyte and parasite vacuole membranes. The
released parasites were washed with ice-cold PBS. P.
yoelii proteins were then solubilized in 50 mM Tris-HCl
pH 8, 50 mM NaCl, 3% CHAPS, 0.5% MEGA10, and
gently mixed at 4°C for 15 min followed by three freeze-
thaw cycles. The supernatants obtained after centrifuga-
tion (13,000 g, 10 min 4°C) were collected and referred
to as parasite extracts. The protein concentration of the
extracts was determined using a Bradford Reagent from
Sigma-Aldrich. 10 μg of parasite proteins were fractio-
nated on 12% SDS-PAGE (Bio-Rad) and transferred
onto PVDF (Hybond-P, GE healthcare) membranes fol-
lowing standard procedures. Blots were incubated with
mice sera antibodies for 2 h at room temperature, fol-
lowed by HRP conjugated anti-mouse IgG (Amersham
Biosciences) at 1/5,000 dilution. Detection was per-
formed using the SuperSignal chemiluminescent sub-
strate (Pierce) and exposure to X-ray film.
Statistical analysis
The statistical analysis of data was performed using Sig-
maPlot11 software. Survival data was analysed using the
Kaplan-Meier statistical method with Log-Rank signifi-
cance test. Statistical significance (P value) of parasitic
load was ascertained by performing t tests. P values <
0.05 were considered statistically significant.
Results
Effects of maslinic acid on a P. yoelii ICR mice model
In a previous report, a parasitostatic effect of MA on P.
falciparum-infected erythrocyte cultures was evidenced
by growth arrest along the ring-trophozoite stages [9].
To assess its possible anti-malarial activity in vivo,
outbred ICR mice were treated by intraperitoneal
administration of MA at 40 mg Kg
-1 following a 4-day
suppressive test protocol. Both survival and parasitaemia
evolution were monitored daily. As shown in the Figure
1, nearly 20% of ICR mice could overcome primary
infection without any experimental intervention. These
surviving mice developed peak parasitaemia levels of
about 60% at day 15, and resolved their infections five
days later. In comparison, the mice which could not
overcome the infection achieved 60% parasitaemia at
d a y6 - 7a n dn o n eo ft h e ms u r v i v e db e y o n dd a y1 0( f i g -
ure 1B). This result suggests the presence of a naturally
resistant subpopulation to P. yoelii in the ICR strain.
Remarkably, the survival rate of ICR mice was signifi-
cantly increased to 80% in the groups treated with MA,
demonstrating the anti-malarial activity of this com-
pound in vivo. Both treated and non-treated ICR mice
which ultimately survived the infection exhibited similar
parasitaemia profiles, showing slower increments
throughout the first five days after infection as
Figure 1 Survival and parasitemia evolution after MA
treatment. ICR mice were infected with 10
7 P. yoelii 17XL infected
RBC and treated 2 hours post-infection with maslinic acid 40 mg
Kg
-1 day
-1, (0.8 mg per mouse per day) for 4 days, starting 2 hours
after infection. A) Survival of treated mice (solid line, n = 10) and
untreated control (dashed line, n = 10). Results are presented as the
survival percent of one representative experiment. P = 0.009
(statistically significant difference between the treated group and
the control); B) Parasitemia dynamics in MA-treated (n = 10) and
non-treated (n = 10) groups. Black circles: Survivors from MA-treated
group; white circles: survivors from non-treated group, and triangles:
non-surviving mice. †: 100% mortality. Results are presented as
mean+SD of one representative experiment. Day 7, P < 0.001
survivors (treated or untreated) vs non-survivors.
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The number of infected erythrocytes in these mice
declined steadily from day 15, and at day 20 no parasites
could be detected microscopically.
The comparison of parasitaemia profiles of cured vs.
not cured mice displayed additional differences. In addi-
tion to lower multiplication rates, the parasite growth
was halted in surviving mice between days 3 and 8 (Fig-
ure 1B). At concentrations corresponding to the IC50,
MA displays a parasitostatic action on P. falciparum-
infected erythrocytes [9]. To ascertain if MA can also
delay the parasite growth in vivo, the distribution of
parasite stages in erythrocytes from day 3 to 8 were ana-
lysed microscopically. As shown in Figure 2, parasites in
MA-treated mice showed a synchronized stage distribu-
tion, as compared to the characteristic lack of synchrony
known for P. yoelii infections, which was observed in
non-survivors. At day 3, ring-stage was the predominant
form, while trophozoites accumulated at day 4 and schi-
zonts at days 5 and 6. Not-treated survivor mice showed
a much less evident divergence in the frequency of schi-
zonts at days 3 to 6, with no significant differences in
ring and trophozoite-stages, suggesting that the mechan-
isms leading to growth delay in the non-treated and
MA-treated mice during the first days of infection may
not be identical. Compared to the 22-25 hours known
to be required to complete a P. yoelii infective cycle in
the erythrocyte [13], MA-treated mice infected erythro-
cytes required nearly 72 hours to reach schizogony from
ring stage, revealing a strong interference of this com-
pound with the parasite maturation.
Parasitaemia course after rechallenge with P. yoelii
To ascertain if mice cured from primary infection
remained protected against subsequent plasmodium
inoculations, survivors from both MA-treated and
untreated subsets were rechallenged at day 40 (18 days
after parasitaemia clearance) with a P. yoelii inoculum
equivalent to the first infection. Parasitaemias were
monitored for 30 additional days. As shown in Figure 3,
no parasites could be detected microscopically in any of
the reinfected mice. All those animals survived, showing
neither malaria symptoms nor detectable parasitaemia,
indicating that they were fully protected against P. yoelii
17XL reinfections, likely by an acquired sterilizing
immunity.
Humoral response in mice after first infection and
rechallenge
To gain some insight on the development of immune
response against P. yoelii both after primary infections
and rechallenge, the concentrations of IgG and IgM
immunoglobulins in sera were determined by ELISA.
The results, shown in Figure 4, revealed that while IgM
concentration remained relatively high in non-treated
mice 30 after first infection, lower concentrations were
detected in MA-treated mice. Furthermore, such differ-
ence in IgM levels was also observed in sera collected
10 days after rechallenge, suggesting a more effective
acquired immune response in MA-treated mice. On the
contrary, IgG values were equivalent in MA-treated and
Figure 2 Distribution of intraerythrocytic parasite stages in ICR
mice. Parasitic stages observed in blood samples from infected ICR
mice. The fraction of ring- (white), trophozoite (dashed) and
schizont-stage (black) iRBC from day 3 to 8 after infection is shown
for non-surviving, non-treated surviving and MA-treated surviving
mice. The data were obtained by microscopic inspection of Wright´
s-stained thin blood smears and compared with controls without
drug. Results are presented as mean+SD of five mice, each one
accounting the percent of cells showing every parasite stage from a
total of 1000 erythrocytes.
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in sera from rechallenged mice as compared to the pri-
mary infection. This reduction may be a consequence of
low induction IgG synthesis due to the minute amount
of parasites in blood, as no newly infected erythrocytes
became apparent after the reinfection.
To get further information on the specific humoral
response, Western-blot analysis of P. yoelii proteins
incubated with sera from both treated and non-treated
mice and anti-mouse IgG-HRP were performed. Sera
f r o ms u r v i v i n gm i c ew e r ec o l l e c t e da td a y3 0a f t e rf i r s t
infection, when no parasites could be detected in blood
smears. The profile of proteins immunodetected with
sera from mice which survived the first infection
revealed the presence of a wide range of antibodies
reacting with P. yoelii antigens (Figure 5). No reacting
antibodies could be seen in uninfected mice. A strong
antigenic band at approximately 45 kDa, and secondary
bands at the 8-20 kDa and 60-200 kDa ranges were
observed in treated mice. Sera from non-treated surviv-
ing mice showed some different pattern, with the stron-
gest signals at 40 kDa and 70 kDa, indicating that the
humoral response in MA treated mice may not be iden-
tical to that of the naturally resistant mice. Sera from
infected mice which do not survive the infection was
collected at day 5, showing two reacting bands at 40
and 20 kDa. This suggests that antibodies binding to
t h e s et w oa n t i g e n sa r ep r o b a b l yt h ef i r s tt ob es y n t h e -
sized, but either they are not able to provide protection
by themselves against the infection, or they are delivered
too late when the rate of parasite growth has reached a
point of no-return.
The immunoreactive protein pattern in mice after
reinfection was also analysed by western-blot of sera
collected at day 10 after the second challenge (Figure 5).
Compared to the blots from the first infection, a large
increase in the signals obtained at high molecular weight
proteins (60-200 kDa) was observed. In addition, the
band at 8 kDa also yields a strong signal in all sera from
cured mice. These results could be explained assuming
that antibodies reacting with those high molecular pro-
teins, and/or the 8 kDa peptide, are produced along the
high-parasitaemia episode in the first infection, leading
to the elimination of the parasite after day 15. Upon
reinfection, the same set of antibodies would be
Days after reinfection




















Figure 3 Parasitemia in reinfected ICR mice.M i c es u r v i v i n g
primary infection from the MA treated (n = 8) and non-treated (n =
8) groups were reinfected at day 40 with 10
7 P. yoelii 17XL, and the
parasitemia was monitored daily for 30 days. White squares: MA-
treated group reinfected; white triangles: untreated group
reinfected; black triangles: naïve mice infected. †: 100% mortality.
Results are presented as mean+SD of one representative
experiment
Figure 4 Parasite-specific IgG and IgM antibody responses of
ICR mice after P. yoelii infection. Mice were infected with 10
7 P.
yoelii 17XL and treated with maslinic acid or left untreated. Sera
from cured mice of the primary infection were collected at day 30.
Sera from not cured mice correspond to day 5 after first infection
(black bars). The surviving mice were reinfected at day 40 and sera
was collected at day 10 after the reinfection (white bars). Results are
presented as mean+SD immunoglobulin concentrations from three
measurements, each containing pooled sera obtained from 6 mice.
Statistical significant differences (P< 0.05) between infected MA-
treated and non-treated groups are indicated by an asterisk.
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infection.
Discussion
Research efforts on the discovery of new anti-malarial
drugs has generated only a handful of successful com-
pounds suitable for the treatment and prevention of
acute symptoms of malaria [14], which are not fully
effective for the overall control of the disease in ende-
mic areas. The search of useful vaccines also remains
elusive despite the many breakthroughs in the molecular
biology, genetics and immunology of Plasmodium infec-
tions. An alternative to these two approaches may lay in
the development of drugs which, while keeping under
control the development of the parasite, would allow the
host immune system to generate a strong response lead-
ing to parasite clearance and, eventually, leave the host
immunized against further reinfections [15,16].
It was previously reported that maslinic acid inhibits
the intraerythrocytic development of P. falciparum in
vitro at ring-trophozoite stages, but does not kill the
parasite, as the removal of the drug allows the infection
to progress [9]. As shown in this report the infection out-
come of P. yoelii-infected mice is also affected by MA.
About one-fifth of outbred ICR population showed to
be naturally able to overcome the acute phase, reduce
parasitaemia to undetectable levels and get cured after
infection with the lethal strain of P. yoelii. Such parasi-
taemia dynamics, in which the density of infected RBC
increases progressively to reach a peak and then
declines, resembles the dynamics of plasmodial infec-
tions in humans, where the majority of infections, even
by lethal P. falciparum strains, course with an acute
phase which is followed by reduction of parasitaemia
levels, to remain as chronic or asymptomatic [1,3]. The
parasitaemia in non-cured ICR mice showed a four-fold
increase in 48 h, while cured ICR displayed a slower
rate, with a doubling time of 4 days. A closer inspection
of the parasitaemia increase in surviving mice during
the first days of infection reveals that the multiplication
of the parasite is practically blocked between days 5 and
11, maintaining during this period a steady parasitaemia
below 30%. After this episode the parasite takes 4 days
to double its blood concentration and then, by day 15,
progressively decay until undetectable levels at day 20.
These results are coherent with previous observations
with non-lethal strains of P. yoelii [17] and P. chabaudi
[1], where CD4
+T helper 1 cells, interferon-g [18] and
proinflamatory cytokine interleukin-12 [19] have been
shown to be required for the control the parasitaemia
within the first 7 to 14 days after infection. The survival
of some 5% of inbred BALB/c mice to lethal P. yoelii
Figure 5 Immunoelectrophoretic analysis of anti-P.yoelii immunoglobulins present in sera from cured and non-cured ICR mice.T o t a l
protein extracts (10 μg) from Py17XL were separated in 12% gradient PAGE-SDS, transferred to PVDF membranes and blotted with pooled sera
from six ICR mice for each indicated infection condition. Reinfection details are indicated in figure 3. Immunoglobulins were visualized using
anti-mouse IgG-HRP.
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parasitaemia peaks (5%) at day 6. In the same report it
was shown that a mixture of B and T cells from surviv-
ing mice was able to provide protection to an X-
radiated, naïve recipient. It has been proposed that the
innate immune mechanism is essential to limit the
initial phase of parasite replication and allowing the host
time to develop antibody-mediated specific adaptative
responses enabling clearance of infection [1]. The pre-
sence of a minor fraction of ICR mice population able
to trigger this innate response in time to avoid the lethal
growth of the parasite may explain the surviving of 20%
of ICR mice.
A four-day MA treatment with a dose of 40 mg Kg
-1
day
-1 after Py7XL infection led to an increase in survival
from 20% to 80% of mice, with a parasitaemia profile
similar to that of the naturally surviving mice. The sim-
plest way to explain the increase in surviving mice asso-
ciated to MA treatment would be to assume that all
ICR mice harbour the required elements to trigger this
innate immune response, but the time window for this
response to be effective is short, in such a way that, in
the majority of the infections of ICR, the parasite fast
growth overcomes the immune response. The parasito-
static effect of MA may take place at this decisive point,
by delaying the maturation of plasmodium at early
stages and providing the system extra time to deploy the
primary response. This is further supported by the
observed parasitostatic effect of MA in vivo, which leads
to the synchronization of Py17XL growth stages in the
first 6 days of infection. As the drug was administered
from day 1 to 4, it is conceivable that newly infected
RBC remained at ring-trophozoite stages during days 3
and 4, starting to reach schizont stage when the drug
concentration in blood decays after treatment. Such
growth hindering would increase the fraction of mice
able to control the parasitaemia and survive. Remark-
ably, no parasite synchronization was observed in non-
cured mice in the same time-period. Cured non-treated
mice showed some decrease in the frequency of schi-
zonts at day 3 followed by a progressive increase up to
day 6, while no apparent differences were observed in
ring and trophozoite distributions. This suggests that
the nonspecific early immune response in the naturally
resistant subpopulation of ICR may be affecting primar-
ily the parasite egress from the schizonts rather than
delaying the maturation at earlier stages.
All ICR mice which survived the primary infection,
independently of treatment, also remained immunized
against rechallenge. This protection prevents any
intraerythrocytic growth of the parasite, as no parasite-
mia was detected even 30 days after reinfection. Earlier
work on ICR infected with avirulent P. yoelii revealed
the induction of long-term immunity against virulent P.
yoelii and Plasmodium berghei [21]. The present results
extend those findings to subpopulations of naturally
resistant ICR mice infected with virulent Plasmodium,
supporting the validity of the observed pattern of
immune response against P. yoelii in mice. Similarly, it
has been shown that chloroquine or artesunate-treated
both resistant DBA/2 infected with lethal Py17XL, or
non-resistant BALB/c infected with non-lethal
Py17XNL, remain immunized against homologous chal-
lenge [22]. These experiments showed no reduction in
rates of parasite appearance after reinfection as com-
pared to untreated control groups. Furthermore, no sig-
nificant differences were observed in that study in IFN-g
or parasite-specific IgG levels in serum. As chloroquine
and artesunate reduce drastically the parasitaemia dur-
ing the first infection, it is likely that this would also
reduce the interaction of the immune system with para-
sitized cells, precluding the heighten of immune
response detected in MA-treated mice.
Remarkably, other experiments carried out using
BALB/c mice infected with lethal P. yoelii [20] showed
that survivor mice remained fully susceptible to re-chal-
lenge infections. This apparent discrepancy with ICR
may be explained considering the low parasitaemia
peaks observed in BALB/c mice (5%) as compared to
ICR (60%). Thus, the lower exposure to parasite anti-
gens in BALB/c may not be sufficient to develop a long-
term immune memory. Accordingly with this possibility,
low doses of parasitocidal drugs, which would allow the
development of parasitaemia during first infection, may
increase the protection against reinfection, as it has
been reported for chloroquine-treated mice infected
with P. berghei [15] and a combination therapy consist-
ing of low doses of interleukin 12 and chloroquine [5].
It is currently accepted that specific adaptative immu-
nity, dependent on B, CD4
+ T and NK cells, and IFN-g,
is required for parasite clearance once the innate non-
specific response manages to control parasitaemia dur-
ing the acute phase in mice [1,23]. The cellular and
humoral response developed at the end of the acute
phase in cured ICR mice may thus provide protection
against further reinfections. IgM levels in serum are sig-
nificantly lower in MA treate mice. As no parasitaemia
could be detected at day 30, the high levels of IgM sur-
viving untreated mice may denote the presence of sub-
microscopic levels of parasites blood. The relatively low
levels of IgM in treated mice as compared to untreated
suggests that, in spite of the similar parasitaemia profiles
in all survivors, the parasite clearance may be more effi-
cient in mice treated with MA. Alternativelly, the differ-
ences in IgM levels may be a consequence of the
seletion exerted by the infection. Thus, mice producing
consistently higher levels of relevant IgM may be those
that survive even without treatment, while individuals
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treated with MA. In any case, MA treatment would be
determinant to increase survival.
The antigenic profiles observed after the primary and
second infections reveal the presence of a wide variety spe-
cific antibodies against P. yoelii antigens. Furthermore, the
comparison of the immunogenic protein profiles from
cured and not cured mice may allow the identification of
potential protective antigens: thus, both high- and low-
molecular weight proteins appear to be highly antigenic in
samples of cured mice 30 days after the first infection, and
antibodies recognizing them are even incremented in the
immunized mice after the reinfection. The identification
of these antigens may provide further insights in the analy-
sis of the protective immune response against malaria.
In human malarial infections asexual intraerythrocytic
stages can induce sterilizing immunity [24-26]. It has
been observed as well that experimental exposure to the
parasite can induce in humans an improved sterilizing
immune response when anti-malarial drug treatment is
co-administered [6]. Moreover, repeated sub-clinical
infections following sporadic drug treatment also facili-
tate the development of immunity to malaria [27]. Thus,
the use of parasitostatic compounds which, like maslinic
acid, enhance the host probability to develop effective
innate and adaptative immunities is worth to be
explored. The characteristics of the acquired immunity
produced by this kind of treatment should be analysed
in terms of long-term protection, cross-immunity and
the effects on non-erythrocytic plasmodial stages.
The elucidation of the targets of maslinic acid would
also allow the selection of a new class of specific drugs
aimed to facilitate the host immune-response. Such
drugs may also be advantageous, as the low selective
pressure exerted on the parasite would prevent the
emergence of resistant variants.
Conclusion
A subpopulation of random-bred ICR mice may develop
natural resistance to P. yoelii infection during the first
days after infection, leading to a slower rate of parasite
growth which, in turn, would facilititate an efficient host
response to infection and parasite clearance. Maslinic acid
appears to enhance the chances to trigger this response in
the treated mice, increasing the fraction of individuals
which can control the parasitaemia and survive the first
infection. Surviving mice from the primary infection
remain protected against reinfection, showing an
enhanced variety of antibodies against P. yoelii antigens.
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